Research programme: prenylcysteine carboxyl methyltransferase inhibitors - PharmaciaAlternative Names: pcCMT inhibitors - Pharmacia; Prenylcysteine carboxyl methyltransferase inhibitors research programme - Pharmacia; Research programme: pcCMT inhibitors - Pharmacia
Latest Information Update: 02 Aug 2002
At a glance
- Originator Pharmacia Corporation
- Mechanism of Action Ras protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 29 Aug 2000 Preclinical development for Cancer in USA (Unknown route)